Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04218695 · ClinicalTrials.gov registry record · Phase 4
Prophylactic Antibiotics in Admitted Cirrhotics
A Phase 4 study of Cirrhosis, Liver, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04218695: Completed Phase 4 study of Cirrhosis, Liver, sponsored by Beth Israel Deaconess Medical Center.
NCT04218695 is a Phase 4 study of Cirrhosis, Liver that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 32 participants, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04218695, a Phase 4 study of Cirrhosis, Liver, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
In this pilot study, the investigators aim to assess feasibility of subject identification and data collection, including specimen processing, as well as the rate of enrollment for a future, larger study of the effect of empiric antibiotics for all patients with advanced cirrhosis admitted to the hospital without an existing indication for new antibiotic use. Specifically, the investigators will assess the incidence of infection after the time of enrollment and associated outcomes. Subjects will be randomly assigned to receive antibiotics vs placebo.
Primary Outcome
Incident bacterial infection after enrollment
Conditions Studied
Interventions
- DRUG Normal saline
- DRUG Ceftriaxone
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-08-24 |
| Est. Completion | 2021-08-28 |
| Phase | Phase 4 |
What the finished NCT04218695 record still lists
NCT04218695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Cirrhosis, Liver appearing as the primary indexed condition, and to 2 interventions - of which Normal saline is the first listed.
NCT04218695 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04218695 about?
NCT04218695 is a clinical study titled "Prophylactic Antibiotics in Admitted Cirrhotics". In this pilot study, the investigators aim to assess feasibility of subject identification and data collection, including specimen processing, as well as the rate of enrollment for a future, larger study of the effect of empiric antibiotics for all patients with advanced cirrhosis admitted to the ho...
What is the current status of trial NCT04218695?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2020-08-24. Estimated completion is 2021-08-28.
What conditions does trial NCT04218695 study?
This clinical trial studies the following conditions: Cirrhosis, Liver.
What interventions are being tested in trial NCT04218695?
The interventions under investigation include: Normal saline (DRUG), Ceftriaxone (DRUG).
Who is sponsoring clinical trial NCT04218695?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04218695 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04218695's enrollment target sits among peer trials
32 26th of 34 higher than 7 of 34 other Cirrhosis, Liver trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis, Liver trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
-
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
RECRUITING · Phase 1
-
Measuring Patient Reported Needs in Outpatient Liver Disease Management
RECRUITING
-
Molecular Mechanism of Exercise in Cirrhosis
RECRUITING · NA
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03530852 · 32 participants · NA
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI